Ljungman P, Duraj V, Magnius L
Department of Medicine, Karolinska Institute, Huddinge, Sweden.
Bone Marrow Transplant. 1991 Feb;7(2):89-93.
Long-term immunity to poliovirus and immunization response to inactivated poliovirus vaccine (IPV) were studied in 55 patients who underwent allogeneic bone marrow transplantation (BMT). Antibodies were determined by neutralization assays. Patients were studied before, at 12 months after BMT and at 12 months after immunization with IPV. Thirty-seven patients were seropositive to all poliovirus types at 12 months after BMT. At least a four-fold decrease in antibody level was recorded between BMT and 12 months later in 55%, 41%, and in 45% of the patients to poliovirus types 1, 2, and 3, respectively. Nineteen patients were immunized with one dose of trivalent IPV. Eight patients (42%), seven patients (36%), and four patients (21%) responded with at least a four-fold antibody titer increase to poliovirus type 1, 2, and 3, respectively. Twenty-nine patients were primarily immunized with three IPV doses. The response rates were 52%, 48% and 48% to poliovirus types 1, 2, and 3, respectively. The immunization responses were similar in patients who did or did not have chronic GVHD. Reimmunization of allogeneic BMT recipients against poliovirus is necessary and a three dose schedule is needed to obtain an adequate immunization response.
对55例接受异基因骨髓移植（BMT）的患者研究了脊髓灰质炎病毒的长期免疫力以及对灭活脊髓灰质炎病毒疫苗（IPV）的免疫反应。通过中和试验测定抗体。在BMT前、BMT后12个月以及IPV免疫后12个月对患者进行研究。37例患者在BMT后12个月时对所有脊髓灰质炎病毒型别血清学阳性。在BMT和12个月后，分别有55%、41%和45%的患者针对脊髓灰质炎病毒1型、2型和3型的抗体水平至少下降了四倍。19例患者接种了一剂三价IPV。分别有8例患者（42%）、7例患者（36%）和4例患者（21%）针对脊髓灰质炎病毒1型、2型和3型的抗体滴度至少升高了四倍。29例患者初次接种三剂IPV。针对脊髓灰质炎病毒1型、2型和3型的应答率分别为52%、48%和48%。有或没有慢性移植物抗宿主病（GVHD）的患者免疫反应相似。异基因BMT受者再次接种脊髓灰质炎疫苗是必要的，并且需要三剂接种方案以获得足够的免疫反应。
